Sign in

You're signed outSign in or to get full access.

Yichun Qian

Research Analyst at Jefferies Financial Group Inc.

Yichun Qian is an Equity Analyst at Jefferies, specializing in biotechnology and pharmaceutical sector research, with a focus on clinical-stage companies such as Karyopharm Therapeutics. Noted for rigorous equity research and financial modeling, Qian has participated in earnings calls and contributes to recommendations that inform institutional investors, although publicly available performance metrics and third-party rankings are limited. Prior to joining Jefferies, Qian held analytical roles within the sector, developing expertise in company fundamentals and sector-specific drivers before transitioning to equity research at Jefferies. Qian holds relevant securities industry credentials and is registered with FINRA, supporting professional analyses and compliance in equity research.

Yichun Qian's questions to Karyopharm Therapeutics (KPTI) leadership

Question · Q1 2025

Yichun Qian, on behalf of Maury Raycroft, asked about the company's confidence in completing myelofibrosis trial enrollment by July, plans for a press release, baseline characteristics of enrolled patients, and patient compliance with daily TSS measurements.

Answer

Richard Paulson, President and CEO, confirmed the company is 80% enrolled and will issue a press release upon reaching its target. Reshma Rangwala, EVP and Chief Medical Officer, added that baseline characteristics are similar to the Phase I trial but with higher baseline TSS scores due to inclusion criteria. She also affirmed that patient compliance with daily electronic TSS reporting is very high due to diligent monitoring.

Ask follow-up questions

Fintool

Fintool can predict Karyopharm Therapeutics logo KPTI's earnings beat/miss a week before the call